- Record Q1 Revenue: Revenue exceeded expectations with net income, EPS, and adjusted EBITDA surpassing guidance ranges.
- Member Engagement Growth: Utilization hit the high end of historical norms, driving strong margins and pregnancy outcomes (e.g., doubled pregnancy effectiveness).
- Full-Year Guidance Raised: Adjusted EBITDA guidance increased to $232M–$244M; net income and EPS also raised amid seasonal engagement consistency.
- Share Repurchase Progress: Completed $200M share buyback program; board evaluating new repurchase options with a decision expected by May.
- Q2 Revenue Forecast: Projected revenue of $342M–$355M (2.7%–6.6% growth) with adjusted EBITDA of $58M–$62M and EPS of $0.31–$0.35.
Revenue & Margin
Revenue climbed to $342 million, driven by a 5.9% to 9% annualized growth trajectory and a 1.04% to 1.05% utilization rate. Gross profit margin held steady, buoyed by lower stock‑compensation expense and ongoing efficiency gains. The company’s cost‑containment strategy, highlighted in the study from a major client, further supports margin resilience.
Earnings & Adjusted EBITDA
Adjusted EBITDA rose to $58–$62 million for Q2, projecting a full‑year range of $232–$244 million. Net income expectations for the year are now $25.8–$28.7 million, with EPS of $0.31–$0.35. These figures align with the company’s guidance that maintains consistent margins across the fiscal year, even as capital expenditures fund platform expansion.
Member Engagement & Utilization
Member engagement remains on a seasonal lift, with utilization pacing typical for the first quarter. The firm’s platform investments—particularly in the Progyny Select offering—are translating into higher member participation, as evidenced by the study that showed doubled pregnancy effectiveness and a 50% reduction in preterm deliveries.
Strategic Partnerships & Pipeline
Progress with health‑plan partners, notably Cigna, and a surge in RFP activity against stand‑alone competitors reinforce Progyny’s market leadership. Early sales commitments and a robust pipeline, including new channel partners, position the company to capture additional share of the women’s health and family‑building market.
Capital Allocation & Share Repurchase
The board is evaluating a new share‑repurchase program, with a decision slated for May. Following the completion of a $200 million buy‑back, the company’s free‑cash‑flow yield of 11.56% signals ample liquidity to fund growth while returning value to shareholders.